G.P. Moloney et al. / European Journal of Medicinal Chemistry 39 (2004) 305–321
321
[12] (a) European Patent EP 0 533 266A1, (1992); (b) European Patent EP
0 533 267 A1, (1992); (c) European Patent EP 0 533 268 A1, J.W.
D.I.C. (1992); (d) Clitherow, M. Scopes, C.C. Skingle, W. Jordan,
I.B. Feniuk, M.C. Campbell, E.W. Carter, H.E. Collington, G.A. Con-
nor, D. Higgins, H.A. Beattie, W.L. Kelly, A.W. Mitchell, A. Oxford,
H. Wadsworth, M.B. Tyers, Evolution of a Novel Series of [(N,N-
Dimethylamino)propyl]- and piperazinylbenzanilides as the first
selective 5-HT1D antagonists, J. Med. Chem. 37 (1994) 2253–2257.
[13] M. Skingle, A.J. Sleight, S. Feniuk, Effects of the 5-HT1D receptor
antagonist GR127935 on extracellular levels of 5-HT in the guinea-
pig frontal cortex as measured by microdialysis, Neuropharmacology
34 (1995) 377–382.
[14] D.M. Walsh, D.T. Beattie, H.E. Connor, The Activity of 5-HT1D
receptor ligands at cloned human 5-HT1Da and 5-HT1Db receptors,
Eur. J. Pharmacol. 287 (1995) 79–84.
[15] E.P. McFadden, J.G. Clarke, G.J. Davies, J.C. Kaski, A.W. Haider,
A. Maseri, Effect of intracoronary serotonin on coronary vessels in
patients with stable angina and patients with variant angina, New.
Eng. J. Med. 324 (1991) 648–654.
(15.0 µl, 0.16 mmol) and TBTU (52.6 mg, 0.16 mmol) were
dissolved in anhydrous DMF (3.0 ml) and stirred at room
temperature under an atmosphere of nitrogen for 30 min.
Diisopropylethylamine (57.0 µl, 0.33 mmol) was added and
the reaction mixture was stirred a further 3 h. The DMF was
evaporated under reduced pressure and the resulting residue
was purified by column chromatography eluting with
(dichloromethane/ethanol/ammonia) (300/8/1) to (60/8/1) to
afford the desired 4-(4-phenethyl-1-piperazinyl)-N-phenyl-
1-benzo[b]thiophene-2-carboxamide (22) as a yellow pow-
der. M.S. m/z 442 (M + 1)+ 1H NMR DMSO-d6) d 2.64 (2H,
m, CH2), 2.78 (4H, m, 2 × CH2), 3.15 (4H, m, 2 × CH2), 6.97
(1H, d, ArH, J = 7.6 Hz), 7.13 (1H, m, ArH), 7.74 (1H, d,
ArH, J = 7.9 Hz), 8.31 (1H, s, ArH), 10.54 (1H, s, NH).
h.p.l.c. retention time = 15.97 min. Linear trace 10% B/90%
D (B = 90% CH3CN/10% H2O) (D = 0.1 N NH4OAc (pH 4)).
[16] P. Golino, F. Piscione, J.T. Willerson, M. Cappelli-Bigazzi, A. Focac-
cio, B. Villari, C. Indolfi, E. Russolillo, M. Condorelli, M. Chiariello,
Divergent effects of serotonin on coronary artery dimensions and
blood flow in patients with coronary atherosclerosis and control
patients, New Eng. J. Med. 324 (1991) 641–648.
References
[17] A. Maseri, Pathogenetic components of acute ischemic syndromes.
Focus on acute ischemic stimuli, Circulation 81 (1 suppl.) (1990)
I1–I3.
[18] D.J. Fitzgerald, L. Roy, F. Catella, G.A. Fitzgerald, Platelet activation
in unstable coronary disease, New Eng. J. Med. 315 (1986) 983–989.
[19] P.B. Bradley, G. Engel, W. Feniuk, J.R. Fozard, P.P.A. Humphrey,
D.N. Middlemiss, E.J. Mylecharane, B.P. Richardson, P.R. Saxena,
Proposals for the classification and nomenclature of functional recep-
tors for 5-hydroxytryptamine, Neuropharmacology 25 (1986) 563–
576.
[20] A.L. Scherbel, J.N. Harrison, Response to serotonin and its antago-
nists in patients with rheumatoid arthritis and related diseases, Angi-
ology 10 (1959) 29–38.
[21] G.P. Moloney, A.D. Robertson, G.R. Martin, S. MacLennan,
N. Mathews, S. Dodsworth, P.Y. Sang, C. Knight, R.C. Glen, A novel
series of 2,5-substituted tryptamine derivatives as vascular 5-HT1B/1D
receptor antagonists, J. Med. Chem. 40 (1997) 2347–2362.
[22] Merrell Dow Pharmaceuticals, PCT/US93/08865.
[23] (a) G.P. Moloney, G.R. Martin, N. Mathews, A. Milne, H. Hobbs,
S. Dodsworth, P.Y. Sang, C. Knight, M. Williams, M. Maxwell,
R.C. Glen, Synthesis and serotonergic activity of substituted 2,N-
benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N,N-
dimethyltryptamine derivatives: novel antagonists for the vascular
5-HT1B-like receptor, J. Med. Chem. 42 (1999) 2504–2526(b)
G.P. Moloney, G.R. Martin, N. Mathews, H. Hobbs, S. Dodsworth,
P.Y. Sang, C. Knight, R.C. Glen, Synthesis and serotonergic activity of
[1] D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin,
E.J. Mylecharane, P.R. Saxena, P.P.A. Humphrey, International union
of pharmacology classification of receptors for 5-hydroxytryptamine
(serotonin), Pharmacol. Rev. 46 (1994) 157–204.
[2] G.R. Martin, P.P.A. Humphrey, Receptors for 5-hydroxy tryptamine:
current perspectives on classification and nomenclature, Neurophar-
macology 33 (1994) 261–273.
[3] D. Hoyer, G.R. Martin, 5-HT receptor classification and
nomenclature: towards a harmonisation with the human genome,
Neuropharmacology 36 (1997) 419–428.
[4] P.M. Vanhoutte, P.P.A. Humphrey, M. Spedding, Recommendations
for nomenclature of new receptor subtypes, Pharmacol. Rev. 48
(1996) 1–2.
[5] P.R. Hartig, D. Hoyer, P.P.A. Humphrey, G.R. Martin, Alignment of
receptor nomenclature with the human genome: classification of
5-HT1B and 5-HT1D receptor subtypes, Trends Pharmacol. Sci. 17
(1996) 103–105.
[6] P.P.A. Humphrey, W. Feniuk, M.J. Perren, H.E. Connor, A.W. Oxford,
I.H. Coates, D. Butina, GR43175, a selective agonist for the 5-HT1-
like receptor in dog isolated saphenous vein, Br. J. Pharmacol. 94
(1988) 1123–1132.
[7] K.L. Dechant, S.P. Clissold, Sumatriptan. A review of its pharmaco-
dynamic and pharmacokinetic properties, and therapeutic efficacy in
the acute treatment of migraine and cluster headache, Drugs 43 (1992)
776–798.
a
series of 2,N-benzylcarboxamido-5-substituted-N,N-dimethyl-
tryptamine derivatives: novel antagonists for the vascular 5-HT1B-like
receptors, J. Chem. Soc. Perkins Trans. 1 (1999) 2173–2723.
[24] R.C. Glen, G.R. Martin, A.P. Hill, R.M. Hyde, P.M. Woollard,
J.A. Salmon, A.D. Robertson, Computer-aided design and synthesis
of 5-substituted tryptamines and their pharmacology at the 5-HT1D
receptor: discovery of compounds with potential anti-migraine prop-
erties, J. Med. Chem. 38 (1995) 3566–3580.
[25] G.R. Martin, S.J. MacLennan, Analysis of the 5-HT receptor in rabbit
saphenous vein exemplifies the problems of using exclusion criteria
for receptor classification, Naunyn. Schmiedebergs.Arch. Pharmacol.
342 (1990) 111–119.
[8] P.C. North, Migraine therapy—serotonin to sumatriptan, in: F.G. King
(Ed.), Medicinal Chemistry: Principles and Practice, The Royal Soci-
ety of Chemistry, 1994.
[9] R.C. Glen, A.P. Hill, G.R. Martin, A.D. Robertson, Computer-aided
design of 5-HT1D agents for the acute treatment of migraine headache,
Headache 34 (1994) 307.
[10] E. Hamel, 5-HT1D receptors: pharmacology and therapeutic potential,
Serotonin ID Research Alert 1 (1996) 19–29.
[11] G.R. Martin, Serotonin Receptor Involvement in the Pathogenesis and
Treatment of Migraine, in: S. Silberstein, P.J. Goadsby (Eds.), Blue
Books on Neurology, Butterworth-Heinemann, Boston,1997.
[26] Sybyl 6.1 molecular modelling package, Tripos Associates, St. Louis,
MO, 1992.